Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary Circulation Diseases Clear all
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 17, 2026, 3:28 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

NCT04207840
View directory record Official record
Conditions
Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis
Interventions
Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation)
Combination Product
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 17, 2026, 3:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications

NCT02094118
View directory record Official record
Conditions
Blood Transfusion Complications
Interventions
Point-of-care washed red blood cell transfusion., Standard of care red blood cell transfusion.
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 17, 2026, 3:28 PM EDT
Completed No phase listed Observational

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

NCT01203423
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Persistent Fetal Circulation Syndrome, Persistent Pulmonary Hypertension of Newborn
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1994
U.S. locations
13
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 17, 2026, 3:28 PM EDT
Active, not recruiting No phase listed Observational

Trans-pulmonary Biomarkers in Pulmonary Hypertension

NCT01961232
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 17, 2026, 3:28 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NCT01720524
View directory record Official record
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions
placebo, iv sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Days to 4 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 17, 2026, 3:28 PM EDT
Completed No phase listed Observational

Cerebral Blood Flow in Single Ventricles Throughout Staged Surgical Reconstruction

NCT02135081
View directory record Official record
Conditions
Single Ventricle Defect
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Months to 10 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 17, 2026, 3:28 PM EDT
Completed Phase 4 Interventional

Inhaled Nitric Oxide by Oxygen Hood in Neonates

NCT00732537
View directory record Official record
Conditions
Respiratory Failure, Infant, Persistent Fetal Circulation
Interventions
inhaled Nitric Oxide, Oxygen (>90% by hood) - standard therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Hour to 1 Week
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2008 · Synced Oct 17, 2026, 3:28 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

NCT00710177
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of the Newborn
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 12 Months
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 17, 2026, 3:28 PM EDT
Withdrawn Phase 1 Interventional

Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow

NCT01825369
View directory record Official record
Conditions
Heart Septal Defects, Ventricular, Atrioventricular Septal Defect
Interventions
IV L-carnitine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Months to 12 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 17, 2026, 3:28 PM EDT
Terminated Phase 4 Interventional

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

NCT00409526
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Inhaled Iloprost
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 7 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 17, 2026, 3:28 PM EDT
Completed No phase listed Observational

Evaluation of Efficacy of the Prototype RPC (Rapid Pulse Confirmation) Device in Detecting Return of Pulsatile Flow in Patients Preparing to Separate From CPB (Cardiopulmonary Bypass)

NCT04526249
View directory record Official record
Conditions
Circulatory Failure, Cardiac Arrest
Interventions
rapid pulse confirmation device
Device
Lead sponsor
Michael Kyle Ritchie
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 17, 2026, 3:28 PM EDT
Completed No phase listed Observational

Antibody Secreting Cell and Cyotokine Profiles in Neonates on ECMO

NCT00371241
View directory record Official record
Conditions
Persistent Fetal Circulation Syndrome, Diaphragmatic Hernia, Meconium Aspiration, Sepsis
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 30 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 17, 2026, 3:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Blood Flow and Vascular Function in Cystic Fibrosis

NCT02057458
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 17, 2026, 3:28 PM EDT
Withdrawn Phase 4 Interventional

Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure

NCT01891500
View directory record Official record
Conditions
Persistent Fetal Circulation Syndrome, Hypertension, Pulmonary, of Newborn, Persistent, Persistent Pulmonary Hypertension of Newborn
Interventions
Inhaled nitric oxide, Nitrogen Gas, Crossover iNO
Drug
Lead sponsor
University of Florida
Other
Eligibility
30 Minutes to 48 Hours
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 17, 2026, 3:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD

NCT02097992
View directory record Official record
Conditions
COPD
Interventions
Roflumilast Placebo, Roflumilast
Drug
Lead sponsor
University of Miami
Other
Eligibility
45 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 17, 2026, 3:28 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia

NCT04597242
View directory record Official record
Conditions
MRSA Bloodstream Infection, MRSA Bacteremia, MRSA Right-sided Endocarditis, Covid19
Interventions
Exebacase
Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years and older
U.S. locations
2
States / cities
Butte, Montana • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 17, 2026, 3:28 PM EDT
Completed Phase 2 Interventional Results available

Milrinone in Congenital Diaphragmatic Hernia

NCT02951130
View directory record Official record
Conditions
Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions
Milrinone, Placebo (5% Dextrose)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
0 Hours to 168 Hours
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 17, 2026, 3:28 PM EDT
Active, not recruiting No phase listed Observational

ET1 Concentration, Metabolic Pathway Activation, and Pulmonary Blood Flow in Infants Undergoing Superior Cavo-Pulmonary Anastomosis

NCT03404258
View directory record Official record
Conditions
Single-ventricle, Pulmonary Vascular Resistance Abnormality, Superior Cavo-Pulmonary Anastomosis, Endothelin, Metabolomics
Interventions
Research Blood Sampling
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Month to 2 Years
Enrollment
50 participants
Timeline
2018 – 2027
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 17, 2026, 3:28 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Sildenafil in Premature Infants

NCT01670136
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of the Newborn
Interventions
1 dose of sildenafil
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Up to 364 Days
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 17, 2026, 3:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Whole Body Periodic Acceleration on Airway Endothelial Function

NCT01213706
View directory record Official record
Conditions
Healthy, Smokers, Asthma
Interventions
Whole Body Periodic Acceleration (WBPA), Sham WBPA
Device
Lead sponsor
University of Miami
Other
Eligibility
20 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 17, 2026, 3:28 PM EDT
Completed Not applicable Interventional Results available

Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma

NCT01210170
View directory record Official record
Conditions
Asthma
Interventions
placebo, mometasone 400 mcg, mometasone 200 mcg
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 17, 2026, 3:28 PM EDT
Terminated Phase 2 Interventional Results available

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

NCT02261883
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of the Newborn
Interventions
IV Remodulin, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
1 Hour to 14 Days
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 17, 2026, 3:28 PM EDT
Completed No phase listed Observational

Hemodynamic Measurements During Liver Transplantation

NCT00682110
View directory record Official record
Conditions
Liver Transplantation
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Oct 17, 2026, 3:28 PM EDT